WealthTrust Axiom’s Genocea Biosciences, Inc. GNCA Stock Holding History

WealthTrust Axiom’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,000	Closed	-$18K	–	276
2022 Q1	$18K	Hold	15,000	–	–	0.01%	263
2021 Q4	$17K	Hold	15,000	–	–	0.01%	264
2021 Q3	$28K	Hold	15,000	–	–	0.01%	252
2021 Q2	$35K	Hold	15,000	–	–	0.01%	263
2021 Q1	$40K	Buy	+15,000	New	+$44.4K	0.01%	247

Other funds holding GNCA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

WealthTrust Axiom's GNCA Position: Q2 2022 in Review

WealthTrust Axiom sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 15,000 shares — an estimated $18K sold.

WealthTrust Axiom first reported a position in GNCA in Q1 2021 and held it in 5 quarters. The position peaked at $40K in Q1 2021. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

WealthTrust Axiom reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
WealthTrust Axiom sold 15,000 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $18K.
WealthTrust Axiom first reported a position in Genocea Biosciences, Inc. in Q1 2021 and held it in 5 quarters.
WealthTrust Axiom's Genocea Biosciences, Inc. position peaked at $40K in Q1 2021.
5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on WealthTrust Axiom's 13F filing for Q2 2022, filed 27 Jul 2022.